LQT-1213 is a first-in-class serum glucocorticoid regulated kinase 1 inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LQT-1213, a first-in-class serum ...
Ninety-five percent of athletes with a diagnosed and treated genetic heart disease experienced no disease-triggered cardiac events, such as cardiogenic fainting or seizures, implantable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback